Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: A prospective, randomized, double-blinded clinical trial

被引:130
|
作者
Heyworth, Benton E. [1 ]
Lee, Jonathan H. [1 ]
Kim, Paul D. [1 ]
Lipton, Carter B. [1 ]
Strauch, Robert J. [1 ]
Rosenwasser, Melvin P. [1 ]
机构
[1] Columbia Univ Coll Phys & Surg, New York Orthopaed Hosp, New York, NY 10032 USA
来源
关键词
basal joint arthritis; corticosteroid; hylan; osteoarthritis; viscosupplementation;
D O I
10.1016/j.jhsa.2007.10.009
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Purpose Conservative, nonsurgical therapies for basal joint osteoarthritis, such as thumb spica splinting and intra-articular corticosteroid injections, remain the mainstays for symptomatic treatment. This study compares intra-articular hylan, corticosteroid, and placebo injections with regard to pain relief, strength, symptom improvement, and metrics of manual function in a randomized, controlled, double-blinded study. Methods Sixty patients with basal joint arthritis were randomized to receive 2 intra-articular hylan injections 1 week apart, 1 placebo injection followed by 1 corticosteroid injection I week later, or 2 placebo injections 1 week apart. Patients were evaluated at 2,4, 12, and 26 weeks and assessed with Visual Analog Scale pain scores, strength measures, difference scores, Disabilities of the Arm, Shoulder, and Hand (DASH) scores, and range of motion measurements. Results All groups reported pain relief at 2 weeks. The steroid and placebo groups had significantly less pain at week 4 compared with baseline, but this effect disappeared by week 12. Only hylan injections continued to provide pain relief at 12 and 26 weeks compared with baseline. There were no significant differences in pain between groups at any time. At 12 and 26 weeks, the hylan group had improved grip strength compared with baseline, whereas the steroid and placebo groups were weaker. At 4 weeks, the steroid group reported in the difference score a greater improvement in symptoms (68%) compared with the hylan (44%) and placebo (50%) groups. Whereas at 26 weeks the hylan group reported the largest improvement in symptoms (68%), this was not statistically different from the placebo (47%) and steroid (58%) groups. There were no significant differences in Disabilities of the Arm, Shoulder, and Hand scores or range of motion among the groups. There were no complications from any injection. Conclusions There were no statistically significant differences among hylan, steroid, and placebo injections for most of the outcome measures at any of the follow-up time points. However, based on the durable relief of pain, improved grip strength, and the long-term improvement in symptoms compared with preinjection values, hylan injections should be considered in the management of basal joint arthritis of the thumb.
引用
收藏
页码:40 / 48
页数:9
相关论文
共 50 条
  • [1] Corticosteroid Injection for the Treatment of Morton's Neuroma: A Prospective, Double-Blinded, Randomized, Placebo-Controlled Trial
    Lizano-Diez, Xavier
    Gines-Cespedosa, Alberto
    Alentorn-Geli, Eduard
    Perez-Prieto, Daniel
    Gonzalez-Lucena, Gemma
    Gamba, Carlo
    de Zabala, Santiago
    Solano-Lopez, Alberto
    Rigol-Ramon, Pau
    [J]. FOOT & ANKLE INTERNATIONAL, 2017, 38 (09) : 944 - 951
  • [2] Surgical Treatment of Lateral Epicondylitis A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
    Kroslak, Martin
    Murrell, George A. C.
    [J]. AMERICAN JOURNAL OF SPORTS MEDICINE, 2018, 46 (05): : 1106 - 1113
  • [3] Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer:a multicenter, randomized,double-blinded,placebo-controlled,phase Ⅱclinical trial
    Rui-Hua Xu
    Lin Shen
    Ke-Ming Wang
    Gang Wu
    Chun-Mei Shi
    Ke-Feng Ding
    Li-Zhu Lin
    Jin-Wan Wang
    Jian-Ping Xiong
    Chang-Ping Wu
    Jin Li
    Yun-Peng Liu
    Dong Wang
    Yi Ba
    Jue-Ping Feng
    Yu-Xian Bai
    Jing-Wang Bi
    Li-Wen Ma
    Jian Lei
    Qing Yang
    Hao Yu
    [J]. 癌症, 2017, 36 (12) : 677 - 685
  • [4] Effectiveness of intramuscular corticosteroid injection versus placebo injection in patients with hip osteoarthritis: design of a randomized double-blinded controlled trial
    Desirée MJ Dorleijn
    Pim AJ Luijsterburg
    Max Reijman
    Margreet Kloppenburg
    Jan AN Verhaar
    Patrick JE Bindels
    P Koen Bos
    Sita MA Bierma-Zeinstra
    [J]. BMC Musculoskeletal Disorders, 12
  • [5] Effectiveness of intramuscular corticosteroid injection versus placebo injection in patients with hip osteoarthritis: design of a randomized double-blinded controlled trial
    Dorleijn, Desiree M. J.
    Luijsterburg, Pim A. J.
    Reijman, Max
    Kloppenburg, Margreet
    Verhaar, Jan A. N.
    Bindels, Patrick J. E.
    Bos, P. Koen
    Bierma-Zeinstra, Sita M. A.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2011, 12
  • [6] A randomized, double blinded, placebo controlled trial of early corticosteroid cessation versus chronic corticosteroid maintenance therapy
    Woodle, ES
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 540 - 541
  • [7] Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial
    Kanokkangsadal, Puritat
    Mingmalairak, Chatchai
    Mukkasombat, Nichamon
    Kuropakornpong, Pranporn
    Worawattananutai, Patsorn
    Khawcharoenporn, Thana
    Sakpakdeejaroen, Intouch
    Davies, Neal M.
    Itharat, Arunporn
    [J]. RESEARCH IN PHARMACEUTICAL SCIENCES, 2023, 18 (06) : 592 - 603
  • [8] Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial
    Chae, John
    Taylor, David McD
    Frauman, Albert G.
    [J]. EMERGENCY MEDICINE AUSTRALASIA, 2011, 23 (05) : 554 - 561
  • [9] Synbiotics and Treatment of Asthma: A Double-Blinded, Randomized, Placebo-Controlled Clinical Trial
    Hassanzad, Maryam
    Mostashari, Keyvan Maleki
    Ghaffaripour, Hosseinali
    Emami, Habib
    Limouei, Samane Rahimi
    Velayati, Ali Akbar
    [J]. GALEN MEDICAL JOURNAL, 2019, 8
  • [10] Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
    Xu, Rui-Hua
    Shen, Lin
    Wang, Ke-Ming
    Wu, Gang
    Shi, Chun-Mei
    Ding, Ke-Feng
    Lin, Li-Zhu
    Wang, Jin-Wan
    Xiong, Jian-Ping
    Wu, Chang-Ping
    Li, Jin
    Liu, Yun-Peng
    Wang, Dong
    Ba, Yi
    Feng, Jue-Ping
    Bai, Yu-Xian
    Bi, Jing-Wang
    Ma, Li-Wen
    Lei, Jian
    Yang, Qing
    Yu, Hao
    [J]. CHINESE JOURNAL OF CANCER, 2017, 36